Biomarker Lens

Biomarkers · Chemical

Noroxycodone, Urine

Understand what Noroxycodone, Urine signals

Primary unit
ng/mg creat
LOINC codes
10998-3, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19648-5, 2161-8, 2756-5, 28073-5, 2965-2, 3390-2, 3393-6, 3394-4, 3508-9, 3681-4, 3725-9, 3831-5, 3879-4, 3887-7, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0, 16249-5, 17395-5, 10976-9, 11235-9, 11247-4, 12308-3, 3414-0, 3507-1, 3539-4, 3773-9, 3830-7, 41858-2, 43199-9, 43219-5, 65807-0, 65808-8, 73566-2, 86453-8, 95135-0, 96059-1, 9834-3, 11071-8, 11230-0, 19346-6, 19695-6, 3349-8, 3377-9, 3426-4, 3530-3, 3774-7, 3780-4, 3926-3, 3936-2, 3937-0, 3950-3, 50542-0, 19593-3, 5644-0, 58378-1, 58425-0, 14267-9, 18355-8, 19570-1, 3415-7, 49753-7, 77207-9
Commercial laboratory assays
13

We have not added a physiological summary for this biomarker yet. Compare the commercial laboratory assays and population reference ranges below.

Compare commercial laboratory assays for Noroxycodone, Urine

Check orderable catalog codes, specimen types, fasting requirements, and demographic reference ranges across laboratories.

Drug Monitoring, Base Panel, with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39421
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19648-5, 2161-8, 2756-5, 28073-5, 2965-2, 3390-2, 3393-6, 3394-4, 3508-9, 3681-4, 3725-9, 3831-5, 3879-4, 3887-7, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39421

Drug Monitoring, Opiates Expanded, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39399
Specimen
Urine
Fasting
Not stated
LOINC
16249-5, 17395-5, 3508-9, 3681-4, 3831-5, 54247-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

Opiates possess exceptional analgesic properties and have become the mainstay of pain management therapies. Being both psychologically and physically addictive, the monitoring of opiate use and abuse is a major component of any treatment program. The test is a definitive assay using liquid chromatography mass spectroscopy (LC/MS/MS) methodology. Therapeutic urine drug monitoring of the opiates is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Codeine<50 ng/mL
Hydrocodone<50 ng/mL
Hydromorphone<50 ng/mL
Morphine<50 ng/mL
Norhydrocodone<50 ng/mL
Noroxycodone<50 ng/mL
Oxycodone<50 ng/mL
Oxymorphone<50 ng/mL
View complete laboratory reference notes

Codeine <50 ng/mL Hydrocodone <50 ng/mL Hydromorphone <50 ng/mL Morphine <50 ng/mL Norhydrocodone <50 ng/mL Noroxycodone <50 ng/mL Oxycodone <50 ng/mL Oxymorphone <50 ng/mL

Quest Diagnostics test directory, test code 39399

Drug Monitoring, Opioids Panel, Quantitative, Urine

Laboratory
Quest Diagnostics
Test code
39012
Specimen
Urine
Fasting
Not stated
LOINC
10976-9, 10998-3, 11235-9, 11247-4, 12308-3, 3414-0, 3507-1, 3539-4, 3773-9, 3830-7, 41858-2, 43199-9, 43219-5, 54247-2, 65807-0, 65808-8, 73566-2, 86453-8, 95135-0, 96059-1, 9834-3

Laboratory assay overview

Monitoring of parent compounds and their metabolites in urine. The results of this test are used in specific treatment programs to determine compliance with prescribed dosing schedules.

Quest Diagnostics population reference ranges

Quest Diagnostics calculates these statistical intervals for this specific assay and demographic group, not as universal optimal targets.

PopulationRange
Buprenorphine<2 ng/mL
Norbuprenorphine<2 ng/mL
Naloxone<2 ng/mL
Fentanyl<0.5 ng/mL
Norfentanyl<0.5 ng/mL
Heroin Metabolite<10 ng/mL
Methadone<100 ng/mL
EDDP<100 ng/mL
Dextromethorphan<20 ng/mL
Dextrorphan<20 ng/mL
Mitragynine<2 ng/mL
Codeine<50 ng/mL
Hydrocodone<50 ng/mL
Hydromorphone<50 ng/mL
Norhydrocodone<50 ng/mL
Morphine<50 ng/mL
Oxycodone<50 ng/mL
Oxymorphone<50 ng/mL
Noroxycodone<50 ng/mL
Tapentadol<50 ng/mL
Nortapentadol<50 ng/mL
Tramadol<100 ng/mL
O-desmethyltramadol<100 ng/mL
View complete laboratory reference notes

Buprenorphine <2 ng/mL Norbuprenorphine <2 ng/mL Naloxone <2 ng/mL Fentanyl <0.5 ng/mL Norfentanyl <0.5 ng/mL Heroin Metabolite <10 ng/mL Methadone <100 ng/mL EDDP <100 ng/mL Dextromethorphan <20 ng/mL Dextrorphan <20 ng/mL Mitragynine <2 ng/mL Codeine <50 ng/mL Hydrocodone <50 ng/mL Hydromorphone <50 ng/mL Norhydrocodone <50 ng/mL Morphine <50 ng/mL Oxycodone <50 ng/mL Oxymorphone <50 ng/mL Noroxycodone <50 ng/mL Tapentadol <50 ng/mL Nortapentadol <50 ng/mL Tramadol <100 ng/mL O-desmethyltramadol <100 ng/mL

Quest Diagnostics test directory, test code 39012

Drug Monitoring, Panel 1, with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39422
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3936-2, 3937-0, 3950-3, 50542-0, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39422

Drug Monitoring, Panel 1, with Confirmation, with D/L Isomers, Urine

Laboratory
Quest Diagnostics
Test code
39426
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3936-2, 3937-0, 3950-3, 50542-0, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39426

Drug Monitoring, Panel 3, with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39423
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19648-5, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3780-4, 3831-5, 3879-4, 3887-7, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39423

Drug Monitoring, Panel 4, with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39424
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3508-9, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3936-2, 3937-0, 3950-3, 50542-0, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39424

Drug Monitoring, Panel 5, with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39425
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3950-3, 50542-0, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39425

Drug Monitoring, Panel 5, with Confirmation, with D/L Isomers, Urine

Laboratory
Quest Diagnostics
Test code
39427
Specimen
Urine
Fasting
Not stated
LOINC
10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3950-3, 50542-0, 54247-2, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39427

Drug Monitoring, Panel 6 with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39428
Specimen
Urine
Fasting
Not stated
LOINC
10976-9, 10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19593-3, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3936-2, 3937-0, 3950-3, 50542-0, 54247-2, 5644-0, 58378-1, 58425-0, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39428

Drug Monitoring, Panel 7 with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39429
Specimen
Urine
Fasting
Not stated
LOINC
10976-9, 10998-3, 11071-8, 11230-0, 11246-6, 12382-8, 12602-9, 15372-6, 19328-4, 19346-6, 19593-3, 19648-5, 19695-6, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3377-9, 3390-2, 3393-6, 3394-4, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3773-9, 3774-7, 3780-4, 3831-5, 3879-4, 3887-7, 3926-3, 3950-3, 50542-0, 54247-2, 5644-0, 58378-1, 58425-0, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39429

Drug Monitoring, Panel 8 with Confirmation, Urine

Laboratory
Quest Diagnostics
Test code
39430
Specimen
Urine
Fasting
Not stated
LOINC
10976-9, 10998-3, 11246-6, 12382-8, 12602-9, 14267-9, 15372-6, 18355-8, 19328-4, 19346-6, 19570-1, 19593-3, 19648-5, 2161-8, 2756-5, 28073-5, 2965-2, 3349-8, 3390-2, 3393-6, 3394-4, 3414-0, 3415-7, 3426-4, 3508-9, 3530-3, 3681-4, 3725-9, 3780-4, 3831-5, 3879-4, 3887-7, 49753-7, 54247-2, 5644-0, 58378-1, 58425-0, 58714-7, 59589-2, 60677-2, 61422-2, 61425-5, 77207-9, 9835-0

Laboratory assay overview

The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive liquid chromatography mass spectroscopy (LC/MS/MS) test. Therapeutic urine drug monitoring is important for ensuring compliance to treatment strategies, as well as ensuring non-diversion for illicit purposes. Urine or oral fluid are the specimens of choice for routine monitoring of patients taking prescription drugs. Use of serum/plasma should be limited to anuretic patients, or where a patient's clinical appearance does not coincide with their prescribed medications. No single monitoring approach provides adequate information about the pattern or dose of patient drug use. Safest prescribing habits should include a combination of tools and laboratory test results to correctly detect drug use patterns. Urine drug test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the drug dose, because the drug is extensively metabolized and excreted in the urine.

View complete laboratory reference notes

See Laboratory Report

Quest Diagnostics test directory, test code 39430

ToxAssure® Flex Oxycodone Class Confirmation, Urine

Laboratory
Labcorp
Test code
912845
Specimen
Urine
Fasting
Not stated
Turnaround
3 - 4 days

Laboratory assay overview

This test is used to detect the presence of prescribed, over-the-counter and illicit drugs for the purpose of medical drug monitoring.

Labcorp test directory, test code 912845

Verify these ranges and sources

We compile every detail above directly from named laboratory directories and published clinical studies. Laboratories calculate standard reference intervals from the statistical distribution of tested populations for a specific assay method and demographic group, rather than setting universal optimal targets.

Always review your personal lab results with a licensed clinician, or track your lab history and health goals in Aumnivida.

Spotted an error? Email hello@biomarkerlens.com with the page URL and the primary source that corrects the entry.